CMS-121 - 10mM in DMSO, high purity , CAS No.1353224-53-9(DMSO)

Item Number

C654537

• Specifications & Purity: 10mM in DMSO
• Biochemical and Physiological Mechanisms: CMS-121 is a quinolone derivative and an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage with EC 50 values of 7 nM and 200 nM, respectively. CMS-121 has strong neuroprotective, ant
• Storage Temp: Store at -80°C
• Shipped In: Ice chest + Ice pads

Product Description

CMS-121 is a quinolone derivative and an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage with EC 50 values of 7 nM and 200 nM, respectively. CMS-121 has strong neuroprotective, anti-inflammatory, antioxidative and renoprotective activities

In Vitro

CMS-121 (1 µM; 4 hours; HT22 cells) treatment increases the phosphorylation of ACC1 at serine 79. CMS-121 can increase acetyl-CoA in cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: HT22 cells Concentration: 1 µM Incubation Time: 4 hours Result: Increases the phosphorylation of ACC1 at serine 79.

In Vivo

CMS-121 (~20 mg/kg; oral administration; daily; for 4 months; female SAMP8 mice) treatment reduces cognitive decline as well as metabolic and transcriptional markers of aging in the brain when administered to rapidly aging SAMP8 mice. CMS-121 preserves mitochondrial homeostasis by regulating acetyl-coenzyme A (acetyl-CoA) metabolism . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female SAMP8 mice (9 months old) Dosage: ~20 mg/kg/day Administration: Oral administration; daily; for 4 months Result: Reduced cognitive decline as well as metabolic and transcriptional markers of aging in the brain.

IC50& Target:Acetyl-CoA carboxylase 1 (ACC1)